Latest Asx And Nzx News

Blackpearl Group more than doubled annual recurring revenue to NZ$26.8 million in FY26, but the growth came alongside an NZ$17.8 million loss and a formal material uncertainty over its ability to continue as a going concern. The company says cost reductions, faster cash conversion and its refinanced BNZ facility can support the next phase.

Vulcan Steel posted a robust FY26 with revenue up 22% and NPAT rising 31%, driven by the integration of Roofing Industries and volume growth despite economic headwinds.

Pacific Edge’s draft Medicare Local Coverage Determination for its Cxbladder bladder cancer tests marks a pivotal step toward unlocking a $10.2 billion global market. Despite FY26 setbacks, the company is poised for growth with improved reimbursement prospects and strategic cost management.

Minerals Exploration Limited has reported rock chip assays with gold grades up to 37.4 g/t and tungsten up to 2.63% at its Glenorchy Tungsten Project in Otago, New Zealand. The company plans a maiden drilling program in late 2026, pending regulatory approvals.

Santana Minerals has reported exceptional high-grade gold intercepts from infill drilling at its Rise and Shine orebody, including a standout 24.4m at 10.9 g/t Au and a deeper 2m section grading 89.5 g/t Au. These results enhance confidence in the deposit’s grade model and the upcoming mining schedule.

AFT Pharmaceuticals has received tentative US FDA approval for its Scomara cream to treat Facial Angiofibromas in Tuberous Sclerosis, but US commercialisation is postponed until 2029 due to orphan drug exclusivity. The approval bolsters regulatory prospects in other key markets where AFT anticipates competitive advantages.

Santana Minerals has reported strong high-grade gold intercepts from initial infill drilling at its Rise and Shine deposit, bolstering confidence in the early-stage open pit mine plan and supporting upcoming financing efforts.

Synlait Milk has locked in a NZ$320 million refinancing package with a broad banking syndicate and replaced its $130 million shareholder loan, while shifting its financial year-end to December to match its major shareholder.

Santana Minerals has voluntarily paused its Bendigo-Ophir Gold Project fast-track approval process to provide additional information following expert panel review, while maintaining the statutory timeline.

EROAD Limited reported stable FY26 revenue of NZD 195 million amid a $134.7 million North American impairment, unveiling a strategic reset centred on ANZ growth and its expanding electronic Road User Charges platform.

AFT Pharmaceuticals surged 22% to NZ$254.7 million revenue in FY26, surpassing profit guidance and securing FDA approval to advance a pivotal injectable iron Phase III trial targeting a $7.4 billion market. The company is poised for further global expansion and product launches in FY27.

Tourism Holdings Limited has allowed the BGH-led consortium to conduct due diligence after a revised all-cash offer of NZ$3.10 per share. The Board remains cautious, with no recommendation or decision yet on the potential acquisition.